Novel bicycloester derivatives and pharmaceutically acceptable salts thereof have high DPP-IV inhibitory activity.
SOLVING MEANS The novel bicycloester derivatives are represented by the general formula (1):
Pharmaceutically acceptable salts thereof are also included (Example: (2S,4S)-1-[[N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)).
The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.
Summary
Novel bicycloester derivatives and pharmaceutically acceptable salts thereof have high DPP-IV inhibitory activity.
Solving Means
The novel bicycloester derivatives are represented by the general formula (1):
Pharmaceutically acceptable salts thereof are also included (Example: (2S,4S)-1-[[(N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)).